Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma
Tracking down targets of the oncogenic epigenetic regulator C-terminal Binding Protein in a mouse pancreatic cancer (PDAC) model led us to ErbB3, highly expressed in up to 60% of PDAC, and the possibility for precision therapy in ErbB3+ PDAC using FDA-approved or novel anti-ErbB2/3 agents.
Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering
We employed CD16 as a biomarker to identify and select Vδ2 T cell PBMC donors. CD16 high Vδ2 T cells were then engineered with a Mesothelin-targeted chimeric antigen receptor and soluble IL-15 for the treatment of ovarian cancers
Is diet-induced hyperinsulinemia and inflammation linked to kidney cancer risk and mortality?
Low-hyperinsulinaemic and high-quality diet as per HEI-2015 can reduce the risk of kidney cancer development, kidney cancer-specific death, and all-cause mortality.
CDK4/6 inhibitors vs. weekly paclitaxel for ER+/HER2- advanced breast cancer with impending or established visceral crisis
In this retrospective study, patients with ER+/HER2- advanced breast cancer and impending or established visceral crisis had better outcomes when treated with a CDK4/6 inhibitor + endocrine therapy compared to weekly paclitaxel.
TRIM69 suppressed the anoikis resistance and metastasis of gastric cancer through ubiquitin‒proteasome-mediated degradation of PRKCD
Oncogene-TRIM69 suppressed the anoikis resistance and metastasis of gastric cancer through ubiquitin‒proteasome-mediated degradation of PRKCD
